http://eprints.utas.edu.au/3610/ Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome Ding, C 320503 Clinical Pharmacology and Therapeutics Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006. 2006 Article PeerReviewed application/pdf http://eprints.utas.edu.au/3610/1/vx-702.pdf http://www.biomedcentral.com/1472-4472/7?issue=11 Ding, C (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Current Opinion in Investigational Drugs, 7 (11). pp. 1020-1025. ISSN 1472-4472 http://eprints.utas.edu.au/3610/http://eprints.utas.edu.au/3610/1/